Lunit Partners with US Guardant Health for Domestic Distribution of Cancer Diagnostic Service..."Cancer Analysis Through Blood"

Gadent360·Gadent Revil Priority Supply
"Diversifying Domestic Market Sales Structure"

Medical AI company Lunit announced on the 7th that it has signed a domestic distribution agreement for cancer diagnostic products with the U.S. bio-healthcare company Guardant Health.

Lunit Signage. [Photo by Lunit]

Through this agreement, the two companies plan to introduce Guardant Health's liquid biopsy and tissue gene analysis services, which precisely analyze cancer using blood, to domestic medical institutions. They will first supply liquid biopsy services such as Guardant360 and Guardant Reveal.

Guardant360 is a test that analyzes Cell-free DNA (cfDNA), small fragments of cancer cell-derived DNA circulating in the blood of patients with advanced solid tumors, using next-generation sequencing (NGS) to detect cancer-specific gene mutations. This test has been approved by the U.S. Food and Drug Administration (FDA) as a comprehensive genomic test for all solid tumors. In particular, it is designated as a companion diagnostic for anticancer therapies such as Tagrisso, Libtayo, Enhertu, Lumakras used in non-small cell lung cancer treatment, and Orserdu, which targets ESR1 mutations in breast cancer.

Guardant Reveal is a test that detects circulating tumor DNA (ctDNA) in the blood to evaluate minimal residual disease (MRD). It helps identify patients with colorectal cancer (stage 2 and 3), lung cancer, breast cancer, and others who are at high risk of recurrence after surgery early on, aiding in determining the optimal treatment plan.

Compared to traditional invasive tissue biopsies, liquid biopsy genomic analysis requires only a simple blood draw, allowing for faster test results and quicker decisions on treatment plans.

Through the domestic launch of Guardant Health's products, Lunit plans to diversify its sales structure in the domestic market. Additionally, it intends to strengthen its partnership with Guardant Health in various fields, including the early introduction of new products currently being pursued.

Seobum Seok, CEO of Lunit, said, "Since establishing an exclusive partnership with Guardant Health in 2021, we have been mutually striving to provide precise cancer diagnostic services, including the global launch of our first co-developed product earlier this year. The distribution network secured through this agreement will greatly assist the domestic distribution of our upcoming AI biomarker platform, 'Lunit Scope.'"

This content was produced with the assistance of AI translation services.